Nolan, Megan, authorNicksic, C., authorTassi, M., authorDavalos, Deana, author2007-01-032007-01-032005http://hdl.handle.net/10217/574Abnormalities of the nicotinic cholinergic system in the brain have been noted in a number of clinical disorders. The higher than average rate of smoking in clinical populations has been theorized as being related to abnormalities in this system. In schizophrenia, the rate of smoking surpasses that of other clinical populations (approximately 80-90% compared to 45-70%). The high rate of smoking, evidence of genetic linkage of schizophrenia to specific nicotinic receptors, and evidence for positive neuropsychological effects of nicotine, all suggest that nicotinic cholinergic mechanisms may play a pathophysiological role in schizophrenia. To assess whether nicotine could normalize early neurophysiological processing in schizophrenia, we studied a measure that has repeatedly been shown to be impaired in this population. The mismatch negativity (MMN) paradigm is an electrophysiological index that has gained interest in recent years as an endophenotype of schizophrenia. MMN measures "preattentive" physiological processes and is elicited by an infrequent change in a repetitive sound. The utility of MMN to assess change in response to pharmacological challenge has been identified by other researchers. However, MMN deficits do not appear to improve with the use of either conventional or atypical medications. Improvements associated with nicotine would suggest a novel change in physiological processing that is unique to nicotinic agonists. To assess the effects of nicotine challenge on MMN amplitude and latency, controls and individuals diagnosed with schizophrenia were administered nicotine gum versus placebo gum during two visits. Subjects underwent a baseline recording on each of the two visits and an additional recording following administration of either nicotine or placebo. Participants were played a series of tones (standard ISI between tones was 500 ms, deviant ISI of 250 ms occurred on average every 20th interval). The average amplitude of MMN waveform elicited by the deviant interval was significantly larger following nicotine administration compared to placebo condition in both the controls and the schizophrenia patients (p<.02). In addition, a significantly greater improvement was noted in the schizophrenia group compared to the controls (p<.05). Finally, symptom checklists suggest that nicotine may alter certain mood states. These results are consistent with the idea that pharmacological agents targeting nicotinic receptors may provide unique physiological benefits that are not addressed by current medications.Student workspostersengCopyright and other restrictions may apply. User is responsible for compliance with all applicable laws. For information about copyright law, please see https://libguides.colostate.edu/copyright.Schizophrenia -- Physiological aspectsNicotinic receptorsNicotine -- Physiological affectNicotine -- Therapeutic use -- TestingNicotine -- AgonistsStillImage